{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Etravirine+%28Intelence%29&page=2",
    "query": {
      "intervention": "Etravirine (Intelence)",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 38,
    "total_pages": 4,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Etravirine+%28Intelence%29&page=3&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Etravirine+%28Intelence%29&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-07T06:43:00.135Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT02016924",
      "title": "Study of Cobicistat-Boosted Atazanavir (ATV/co), Cobicistat-Boosted Darunavir (DRV/co) and Emtricitabine/Tenofovir Alafenamide (F/TAF) in Children With HIV",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Acquired Immune Deficiency Syndrome (AIDS)",
        "HIV Infections"
      ],
      "interventions": [
        {
          "name": "ATV",
          "type": "DRUG"
        },
        {
          "name": "DRV",
          "type": "DRUG"
        },
        {
          "name": "Cobicistat",
          "type": "DRUG"
        },
        {
          "name": "BR",
          "type": "DRUG"
        },
        {
          "name": "F/TAF",
          "type": "DRUG"
        },
        {
          "name": "LPV/r",
          "type": "DRUG"
        },
        {
          "name": "Third Unboosted Drug",
          "type": "DRUG"
        },
        {
          "name": "Cobicistat TOS",
          "type": "DRUG"
        },
        {
          "name": "F/TAF TOS",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Gilead Sciences",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "4 Weeks",
        "maximum_age": "17 Years",
        "sex": "ALL",
        "summary": "4 Weeks to 17 Years"
      },
      "enrollment_count": 133,
      "start_date": "2014-01-16",
      "completion_date": "2027-03",
      "has_results": false,
      "last_update_posted_date": "2026-04-21",
      "last_synced_at": "2026-10-07T06:43:00.135Z",
      "location_count": 7,
      "location_summary": "Long Beach, California • Los Angeles, California • Aurora, Colorado + 4 more",
      "locations": [
        {
          "city": "Long Beach",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02016924"
    },
    {
      "nct_id": "NCT00460746",
      "title": "Enfuvirtide/Current Protease Inhibitor Switch to PREZISTA (Darunavir)/Ritonavir + TMC125 in HIV Patients With Enfuvirtide Side Effects.",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "HIV"
      ],
      "interventions": [
        {
          "name": "TMC125, Darunavir; Ritonavir",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Tibotec, Inc",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 10,
      "start_date": "2007-05",
      "completion_date": "2008-10",
      "has_results": true,
      "last_update_posted_date": "2013-07-31",
      "last_synced_at": "2026-10-07T06:43:00.135Z",
      "location_count": 1,
      "location_summary": "Los Angeles, California",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00460746"
    },
    {
      "nct_id": "NCT01276236",
      "title": "Effects of Maraviroc (MVC) on HIV-related Kaposi's Sarcoma (KS)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Kaposi's Sarcoma"
      ],
      "interventions": [
        {
          "name": "Maraviroc",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of California, San Francisco",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 13,
      "start_date": "2011-03-09",
      "completion_date": "2015-04-30",
      "has_results": true,
      "last_update_posted_date": "2021-03-05",
      "last_synced_at": "2026-10-07T06:43:00.135Z",
      "location_count": 1,
      "location_summary": "San Francisco, California",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01276236"
    },
    {
      "nct_id": "NCT00359021",
      "title": "An Open-label Trial With TMC125 in Patients Who Have Virologically Failed in a DUET Trial (TMC125-C206 or TMC125-C216).",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "HIV-1"
      ],
      "interventions": [
        {
          "name": "TMC125",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Tibotec Pharmaceuticals, Ireland",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 503,
      "start_date": "2006-06",
      "completion_date": "2012-01",
      "has_results": true,
      "last_update_posted_date": "2014-05-16",
      "last_synced_at": "2026-10-07T06:43:00.135Z",
      "location_count": 32,
      "location_summary": "Phoenix, Arizona • Little Rock, Arkansas • Beverly Hills, California + 29 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Beverly Hills",
          "state": "California"
        },
        {
          "city": "Long Beach",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00359021"
    },
    {
      "nct_id": "NCT01822522",
      "title": "Cabozantinib S-Malate in Treating Patients With Advanced Solid Tumors and Human Immunodeficiency Virus",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Advanced Malignant Solid Neoplasm",
        "HIV Infection",
        "Metastatic Malignant Solid Neoplasm",
        "Recurrent Malignant Solid Neoplasm",
        "Unresectable Solid Neoplasm"
      ],
      "interventions": [
        {
          "name": "Cabozantinib S-malate",
          "type": "DRUG"
        },
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        },
        {
          "name": "Pharmacological Study",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 36,
      "start_date": "2013-06-21",
      "completion_date": "2021-05-12",
      "has_results": true,
      "last_update_posted_date": "2023-01-10",
      "last_synced_at": "2026-10-07T06:43:00.135Z",
      "location_count": 20,
      "location_summary": "La Jolla, California • Los Angeles, California • San Diego, California + 9 more",
      "locations": [
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Honolulu",
          "state": "Hawaii"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01822522"
    },
    {
      "nct_id": "NCT00980538",
      "title": "TMC125-TiDP35-C239 - Continued Access to Etravirine (ETR) in Treatment Experienced HIV-1 Infected Participants",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "HIV Infections",
        "HIV-1"
      ],
      "interventions": [
        {
          "name": "Etravirine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Janssen Sciences Ireland UC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "2 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "2 Years and older"
      },
      "enrollment_count": 180,
      "start_date": "2009-12-09",
      "completion_date": "2026-04-08",
      "has_results": true,
      "last_update_posted_date": "2026-06-09",
      "last_synced_at": "2026-10-07T06:43:00.135Z",
      "location_count": 4,
      "location_summary": "Los Angeles, California • Washington D.C., District of Columbia • New York, New York + 1 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00980538"
    },
    {
      "nct_id": "NCT00665847",
      "title": "TMC125-TiDP35-C213: Safety and Antiviral Activity of Etravirine (TMC125) in Treatment-Experienced, HIV Infected Children and Adolescents",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "HIV-1"
      ],
      "interventions": [
        {
          "name": "Etravirine (TMC125)",
          "type": "DRUG"
        },
        {
          "name": "Optimized background regimen (OBR)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Tibotec Pharmaceuticals, Ireland",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "6 Years",
        "maximum_age": "17 Years",
        "sex": "ALL",
        "summary": "6 Years to 17 Years"
      },
      "enrollment_count": 103,
      "start_date": "2008-11",
      "completion_date": "2011-08",
      "has_results": true,
      "last_update_posted_date": "2015-04-23",
      "last_synced_at": "2026-10-07T06:43:00.135Z",
      "location_count": 13,
      "location_summary": "Mobile, Alabama • Los Angeles, California • Washington D.C., District of Columbia + 10 more",
      "locations": [
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "New Orleans",
          "state": "Louisiana"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00665847"
    },
    {
      "nct_id": "NCT04630002",
      "title": "Drug-drug Interaction (DDI) Study of GSK3640254 With Darunavir/Ritonavir (DRV/RTV) and Etravirine (ETR)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "HIV Infections"
      ],
      "interventions": [
        {
          "name": "GSK3640254",
          "type": "DRUG"
        },
        {
          "name": "Darunavir/Ritonavir (DRV/RTV)",
          "type": "DRUG"
        },
        {
          "name": "Etravirine (ETR)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "ViiV Healthcare",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "18 Years to 50 Years"
      },
      "enrollment_count": 54,
      "start_date": "2020-10-28",
      "completion_date": "2021-10-02",
      "has_results": true,
      "last_update_posted_date": "2024-08-29",
      "last_synced_at": "2026-10-07T06:43:00.135Z",
      "location_count": 1,
      "location_summary": "Austin, Texas",
      "locations": [
        {
          "city": "Austin",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04630002"
    },
    {
      "nct_id": "NCT00855335",
      "title": "A Single-arm, Open-label, Study to Assess the Pharmacokinetics of Darunavir and Ritonavir, Darunavir and Cobicistat, Etravirine, and Rilpivirine in HIV-1 Infected Pregnant Women",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "HIV",
        "HIV Infections",
        "Pregnancy"
      ],
      "interventions": [
        {
          "name": "Darunavir",
          "type": "DRUG"
        },
        {
          "name": "Ritonavir",
          "type": "DRUG"
        },
        {
          "name": "Etravirine",
          "type": "DRUG"
        },
        {
          "name": "Rilpivirine",
          "type": "DRUG"
        },
        {
          "name": "Darunavir/Cobicistat (FDC)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Janssen Scientific Affairs, LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 77,
      "start_date": "2009-04-09",
      "completion_date": "2016-08-11",
      "has_results": true,
      "last_update_posted_date": "2018-07-06",
      "last_synced_at": "2026-10-07T06:43:00.135Z",
      "location_count": 16,
      "location_summary": "Daytona Beach, Florida • Jacksonville, Florida • Miami, Florida + 13 more",
      "locations": [
        {
          "city": "Daytona Beach",
          "state": "Florida"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Pensacola",
          "state": "Florida"
        },
        {
          "city": "Port Saint Lucie",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00855335"
    },
    {
      "nct_id": "NCT00042289",
      "title": "Pharmacokinetic Study of Antiretroviral Drugs and Related Drugs During and After Pregnancy",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "HIV Infections"
      ],
      "interventions": [
        {
          "name": "atazanavir/cobicistat",
          "type": "DRUG"
        },
        {
          "name": "darunavir/ritonavir dosage #1",
          "type": "DRUG"
        },
        {
          "name": "darunavir/ritonavir dosage #2",
          "type": "DRUG"
        },
        {
          "name": "darunavir/ritonavir dosage #3",
          "type": "DRUG"
        },
        {
          "name": "elvitegravir/cobicistat",
          "type": "DRUG"
        },
        {
          "name": "dolutegravir",
          "type": "DRUG"
        },
        {
          "name": "tenofovir alafenamide fumarate (TAF)",
          "type": "DRUG"
        },
        {
          "name": "TAF w/cobicistat",
          "type": "DRUG"
        },
        {
          "name": "TAF w/cobicistat or ritonavir",
          "type": "DRUG"
        },
        {
          "name": "efavirenz",
          "type": "DRUG"
        },
        {
          "name": "darunavir/cobicistat",
          "type": "DRUG"
        },
        {
          "name": "lopinavir/ritonavir dosage #1",
          "type": "DRUG"
        },
        {
          "name": "atazanavir/ritonavir/tenofovir dosage #1",
          "type": "DRUG"
        },
        {
          "name": "rifampicin",
          "type": "DRUG"
        },
        {
          "name": "ethambutol",
          "type": "DRUG"
        },
        {
          "name": "isoniazid",
          "type": "DRUG"
        },
        {
          "name": "pyrazinamide",
          "type": "DRUG"
        },
        {
          "name": "kanamycin",
          "type": "DRUG"
        },
        {
          "name": "amikacin",
          "type": "DRUG"
        },
        {
          "name": "capreomycin",
          "type": "DRUG"
        },
        {
          "name": "moxifloxacin",
          "type": "DRUG"
        },
        {
          "name": "levoflaxacin",
          "type": "DRUG"
        },
        {
          "name": "ofloxacin",
          "type": "DRUG"
        },
        {
          "name": "ethionamide/prothionamide",
          "type": "DRUG"
        },
        {
          "name": "terizidone/cycloserine",
          "type": "DRUG"
        },
        {
          "name": "para-aminosalicylic acid (PAS)",
          "type": "DRUG"
        },
        {
          "name": "high dose INH",
          "type": "DRUG"
        },
        {
          "name": "bedaquiline",
          "type": "DRUG"
        },
        {
          "name": "clofazamine",
          "type": "DRUG"
        },
        {
          "name": "delamanid",
          "type": "DRUG"
        },
        {
          "name": "linezolid",
          "type": "DRUG"
        },
        {
          "name": "pretomanid",
          "type": "DRUG"
        },
        {
          "name": "ethinyl estradiol",
          "type": "DRUG"
        },
        {
          "name": "etonogestrel implant",
          "type": "DRUG"
        },
        {
          "name": "nevirapine",
          "type": "DRUG"
        },
        {
          "name": "amprenavir",
          "type": "DRUG"
        },
        {
          "name": "abacavir",
          "type": "DRUG"
        },
        {
          "name": "lopinavir/ritonavir dosage #2",
          "type": "DRUG"
        },
        {
          "name": "indinavir/ritonavir dosage #1",
          "type": "DRUG"
        },
        {
          "name": "fosamprenavir/ritonavir",
          "type": "DRUG"
        },
        {
          "name": "lopinavir/ritonavir dosage #3",
          "type": "DRUG"
        },
        {
          "name": "atazanavir/ritonavir dosage #1",
          "type": "DRUG"
        },
        {
          "name": "didanosine delayed release (Videx® EC)",
          "type": "DRUG"
        },
        {
          "name": "emtricitabine",
          "type": "DRUG"
        },
        {
          "name": "tenofovir",
          "type": "DRUG"
        },
        {
          "name": "nelfinavir dosage #1",
          "type": "DRUG"
        },
        {
          "name": "tipranavir/ritonavir",
          "type": "DRUG"
        },
        {
          "name": "lopinavir/ritonavir dosage #4",
          "type": "DRUG"
        },
        {
          "name": "raltegravir",
          "type": "DRUG"
        },
        {
          "name": "etravirine",
          "type": "DRUG"
        },
        {
          "name": "maraviroc",
          "type": "DRUG"
        },
        {
          "name": "atazanavir/ritonavir dosage #2",
          "type": "DRUG"
        },
        {
          "name": "tenofovir/atazanavir/ritonavir dosage #2",
          "type": "DRUG"
        },
        {
          "name": "nelfinavir dosage #2",
          "type": "DRUG"
        },
        {
          "name": "indinavir/ritonavir dosage #2",
          "type": "DRUG"
        },
        {
          "name": "rilpivirine",
          "type": "DRUG"
        },
        {
          "name": "darunavir/ritonavir dosage #4",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 1578,
      "start_date": "2003-06-09",
      "completion_date": "2020-09-30",
      "has_results": true,
      "last_update_posted_date": "2025-12-02",
      "last_synced_at": "2026-10-07T06:43:00.135Z",
      "location_count": 39,
      "location_summary": "Birmingham, Alabama • La Jolla, California • Long Beach, California + 26 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Long Beach",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00042289"
    }
  ]
}